Reuters logo
BRIEF-InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017
August 28, 2017 / 8:52 PM / 24 days ago

BRIEF-InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017

Aug 28 (Reuters) - InVivo Therapeutics Holdings Corp

* InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​

* InVivo Therapeutics Holdings Corp says ‍restructuring is expected to extend company’s cash runway into beginning of Q3 of 2018 - SEC filing​

* InVivo Therapeutics Holdings - ‍expects restructuring will result in total restructuring charges of about $810,000-$1.1 million during year ending Dec 31, 2017

* InVivo Therapeutics Holdings-on Aug 28, co notified Thomas Ulich, co's chief scientific officer,that his employment to be terminated effective Aug 30, 2017​ Source text: [bit.ly/2wY8uzK] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below